Immatics is a clinical-stage biopharmaceutical company active in the discovery and development of T-cell
redirecting immunotherapies for the treatment of cancer.
One of the key objectives of the report was to estimate the existing market size and identify potential growth opportunities for T-cell
immunotherapies over the coming decade.
Cancer cell Normal cells T-cells
are part of our immune system.
According to the authors, the findings suggest a novel mechanism in which HBeAg-induced MDSC expansion impairs T-cell
function through the IDO pathway and favours the establishment of persistent HBV infection.
prolymphocytic leukemia (T-PLL) affects approximately 2% of all patients with mature lymphocytic leukemias.
TCR therapy differs from CAR T-cell
therapy in that the latter involves creating receptors that are not found in nature.
The product uses the company's proprietary ARTEMIS T-cell
receptor platform engineered with a proprietary human TCR-mimic antibody to target an AFP-peptide/HLA-A2 complex on hepatocellular carcinoma cancer cells.
Monomorphic epitheliotropic intestinal T-cell
lymphoma (MEITL) was formerly known as "type II" enteropathy-associated T-cell
therapies contain a mixture of CD4 and CD8 cells.
BPX-501 is an adjunct T-cell
therapy administered after allogeneic hematopoietic stem cell transplant (HSCT) comprising genetically modified donor T cells incorporating Bellicum's Cas-paCIDe safety switch.
In previous findings, HAM/TSP progression was associated with T-cell
activation in the spinal cord, leading to an inflammatory process and demyelinization.
The flow cytometry analysis detected an abnormal T-cell
phenotype expressing CD45, cCD3, bright surface CD7, CD43, partial CD2, two myeloid markers (CD13 and CD33), dim/partial TdT, and, to a lesser extent, CD1a, while lacking sCD3, CD4, CD8, CD5, and defining markers for myeloid, monocytic, and B-lymphoid lineage (MPO-, CD14-, CD64-, CD11b-, CD19-, and CD20-) (Figure 2(c)).